http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#Head http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#assertion http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#provenance http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#pubinfo http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#assertion http://purl.obolibrary.org/obo/DOID_893 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_893 http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06824 http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association http://www.w3.org/2000/01/rdf-schema#label trientine hydrochloride capsule is indicated in the treatment of patients with wilson s disease who are intolerant of penicillamine clinical experience with trientine hydrochloride capsule is limited and alternate dosing regimens have not been well characterized all endpoints in determining an individual patient s dose have not been well defined trientine hydrochloride capsule and penicillamine cannot be considered interchangeable trientine hydrochloride capsule should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects unlike penicillamine trientine hydrochloride capsule is not recommended in cystinuria or rheumatoid arthritis the absence of a sulfhydryl moiety renders it incapable of binding cystine and therefore it is of no use in cystinuria in 15 patients with rheumatoid arthritis trientine hydrochloride capsule was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment trientine hydrochloride capsule is not indicated for treatment of biliary cirrhosis http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06824 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#provenance http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#pubinfo http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#sig http://purl.org/nanopub/x/hasSignature EKa4SuSeAqeljsbsjC74Q3VaC0Ql7x4RPYTPRibY6W2j5qRlZFyKoAI6lXogGjI69v6qvS5LWs88tnHCEt4jYaHLCcMhUsjqIj5gO3axzd4gXBodGa1syydNC/5R4yLpdBrKIDmqISvQ3xBG8Eydq5jD6GUbFVtuPdevFzGp+6E= http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://purl.org/dc/terms/created 2021-06-13T12:48:34.141+02:00 http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA9MZGq_4-yhNS3GpBmwGp9EzDE_UFZyERMiuoU1CUxiE https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs